SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of hypoglycemic drugs that have been shown to improve cardiovascular outcomes in type 2 diabetes mellitus (T2DM) (Zinman et al., 2015; Neal et al., 2017; Wiviott et al., 2019).